Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.

Autor: Cicin, Irfan1 (AUTHOR) irfancicin@trakya.edu.tr, Plimack, Elizabeth R.2 (AUTHOR), Gurney, Howard3 (AUTHOR), Leibowitz, Raya4,5 (AUTHOR), Alekseev, Boris Y.6 (AUTHOR), Parnis, Francis X.7 (AUTHOR), Peer, Avivit8 (AUTHOR), Necchi, Andrea9 (AUTHOR), Bellmunt, Joaquim10 (AUTHOR), Nishiyama, Hiroyuki11 (AUTHOR), Clark, Jason12 (AUTHOR), Munteanu, Mihaela12 (AUTHOR), Kataria, Ritesh13 (AUTHOR), Jia, Calvin13 (AUTHOR), Powles, Thomas14 (AUTHOR), Sternberg, Cora N.15 (AUTHOR)
Zdroj: BMC Cancer. 7/25/2024, Vol. 23 Issue 1, p1-11. 11p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje